Cost-effectiveness analysis of malaria interventions using disability adjusted life years: A systematic review

Cost Effectiveness and Resource Allocation

Volumn 15, Issue 1, 2017, Pages

  Gunda, Resign ^a   Chimbari, Moses John ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Cost; Cost effectiveness; Disability adjusted life years; Effectiveness; Malaria

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMISININ; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; DAPSONE PLUS PYRIMETHAMINE; MALARIA VACCINE; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

AFRICA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISABILITY ADJUSTED LIFE YEAR; EARLY DIAGNOSIS; EDUCATION PROGRAM; ENVIRONMENTAL MANAGEMENT; GLOBAL DISEASE BURDEN; HUMAN; INSECTICIDE TREATED NET; MALARIA; MALARIA CONTROL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; VECTOR CONTROL;

EID: 85021655523     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-017-0072-9     Document Type: Review

References (59)

1. WHO. World malaria report. Geneva: WHO; 2015.
2. Githeko AK, Ndegwa W. Predicting malaria epidemics in the Kenyan highlands using climate data: a tool for decision makers. Glob Chang Hum Health. 2001;2(1):54-63.
3. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354(9176):378-85.
4. Evans DB, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 2005;331(7525):1137-40.
5. Galarraga O, et al. HIV prevention cost-effectiveness: a systematic review. BMC Public Health. 2009;9(Suppl 1):S5.
6. Chisin R. Cost-effectiveness analysis. J Nucl Med. 2009;50(3):338-9.
7. Creese A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635-43.
8. Lubell Y, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89(7):504-12.
9. Bener A, et al. Measuring burden of diseases in a rapidly developing economy: state of Qatar. Glob J Health Sci. 2013;5(2):134-44.
10. Murray CJL, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1st ed. Cambridge: Harvard University Press; 1996.
11. Murray CJ, Lopez AD, editors. The Global Burden of Disease. Havard School of Public Health: Geneva; 1998. p. 1-46.
12. Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life year (daly). Methods and tools in public health. In: Zaletel-Kragelj L, Boţikov J, editors. A handbook for teachers, researchers and health professionals. Lage: Hans Jacobs Publishing Company; 2010.
13. Murray CJ, et al. GBD 2010: design, definitions, and metrics. Lancet. 2012;380(9859):2063-6.
14. Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. 2nd ed. Cambridge: Harvard University Press; 1996.
15. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray DB, Murray CJL, editors. Geneva: WHO; 2003.
16. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123-30.
17. Edwards C. Cost-effectiveness analysis in practice. In: Hunter P, Cameron J, Jagals P, Pond K, editors. Valuing water, valuing livelihoods. London: IWA Publishing; 2011. p. 181-197.
18. WHO. Investing in health research and development: report of the ad hoc committee on health research relating to future intervention options. Geneve: WHO; 1996.
19. Mueller DH, et al. Costs of early detection systems for epidemic malaria in highland areas of Kenya and Uganda. Malar J. 2009;8:17.
20. GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145-91.
21. Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS ONE. 2014;9(4):e95681.
22. Buchanan J, et al. Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. PLoS ONE. 2010;5(12):e14446.
23. Mori AT, et al. Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J. 2014;13:363.
24. Tediosi F, et al. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in Sub-Saharan Africa. Am J Trop Med Hyg. 2006;75(2 Suppl):90-103.
25. Tozan Y, et al. Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis. Lancet. 2010;376(9756):1910-5.
26. Wolfe EB, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg. 2001;64(3-4):178-86.
27. Akhavan D, et al. Cost-effective malaria control in Brazil: cost-effectiveness of a malaria control program in the Amazon Basin of Brazil, 1988-1996. Soc Sci Med. 1999;49(10):1385-99.
28. Utzinger J, Tozan Y, Singer BH. Efficacy and cost-effectiveness of environmental management for malaria control. Trop Med Int Health. 2001;6(9):677-87.
29. Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ. 2005;331(7528):1299.
30. Stuckey EM, et al. Modeling the cost effectiveness of malaria control interventions in the highlands of western Kenya. PLoS ONE. 2014;9(10):e107700.
31. Hutton G. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ. 2009;87(2):123-9.
32. Conteh L, et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS ONE. 2010;5(6):e10313.
33. Alonzo Gonzalez M, et al. Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants. Bull World Health Organ. 2000;78(1):97-107.
34. Maire N, et al. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health. 2011;14(8):1028-38.
35. Nunes JK, et al. Modeling the public health impact of malaria vaccines for developers and policymakers. BMC Infect Dis. 2013;13:295.
36. Penny MA, et al. Public health impact and cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387(10016):367-75.
37. Ross A, et al. Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLoS ONE. 2011;6(4):e18391.
38. Sicuri E, et al. Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS ONE. 2010;5(10):e13407.
39. Tediosi F, et al. Simulation of the cost-effectiveness of malaria vaccines. Malar J. 2009;8:127.
40. Seo MK, Baker P, Ngo KN. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets. Malar J. 2014;13:66.
41. Maheu-Giroux M, Castro MC. Cost-effectiveness of larviciding for urban malaria control in Tanzania. Malar J. 2014;13:477.
42. Yukich JO, et al. Costs and consequences of large-scale vector control for malaria. Malar J. 2008;7:258.
43. Becker-Dreps SI, et al. Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republic of the Congo. Am J Trop Med Hyg. 2009;81(3):496-502.
44. Briet OJ, Chitnis N. Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study. Malar J. 2013;12:215.
45. Briet OJ, et al. Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study. Malar J. 2013;12:77.
46. Coleman PG, Goodman CA, Mills A. Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Trop Med Int Health. 1999;4(3):175-86.
47. Kahn JG, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS ONE. 2012;7(2):e31316.
48. Mueller DH, et al. Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. Malar J. 2008;7:73.
49. Yukich JO, et al. Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bed nets. Malar J. 2009;8:51.
50. Utzinger J, et al. The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950. Trop Med Int Health. 2002;7(8):657-77.
51. Chen IT, et al. Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar. Malar J. 2015;14:55.
52. Shillcutt S, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86(2):101-10.
53. Goodman CA, et al. The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya. Health Policy Plan. 2006;21(4):275-88.
54. Sun DW, et al. A cost-effectiveness analysis of Plasmodium falciparum malaria elimination in Hainan Province, 2002-2012. Am J Trop Med Hyg. 2015;93(6):1240-8.
55. Pfeil J, et al. An economic evaluation of the posttreatment prophylactic effect of dihydroartemisinin-piperaquine versus artemether-lumefantrine for first-line treatment of Plasmodium falciparum malaria across different transmission settings in Africa. Am J Trop Med Hyg. 2015;93(5):961-6.
56. Fernandes S, et al. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data. Lancet Glob Health. 2015;3(3):e143-53.
57. WHO. Intermittent preventive treatment in pregnancy (IPTp): key documents and guidelines. 2016. http://www.who.int/malaria/areas/preventive_therapies/pregnancy/en/.
58. Sicuri E, et al. Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. PLoS ONE. 2015;10(4):e0125072.
59. Marseille E, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118-24.